Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial
Langzeitwirkungen glukosesenkender Medikamente auf β-Zell-Antworten und Insulinempfindlichkeit bei Typ-2-Diabetes: GRADE-RCT
Diabetes Care · 01.04.2024 · 47 (4) · 580-588
DOI: 10.2337/dc23-1070 ↗Auf einen Blick
Bei 4.801 Menschen mit Typ-2-Diabetes unterschieden sich die Langzeiteffekte von Insulin glargin U-100, Glimepirid, Liraglutid und Sitagliptin auf Insulinempfindlichkeit und β-Zell-Funktion.
Fragestellung
Wie unterscheiden sich die langfristigen Effekte von Insulin glargin U-100, Glimepirid, Liraglutid und Sitagliptin zusätzlich zu Metformin auf Insulinempfindlichkeit und β-Zell-Funktion?
Methode
GRADE-Kohorte mit Typ-2-Diabetes (n = 4.801); HOMA2 und orale Glukosetoleranztests zu Baseline sowie nach 1, 3 und 5 Jahren.
Ergebnisse
HOMA2-%S stieg mit Glargin bis Jahr 1 und blieb stabil; in den anderen Gruppen änderte es sich nicht. HOMA2-%B und C-Peptid-Antworten stiegen zunächst, nahmen dann ab. Nach 5 Jahren war CPI bei Liraglutid und Sitagliptin höher als bei Glargin und Glimepirid (P < 0,001).
Schlussfolgerung der Autor:innen
Die unterschiedlichen Langzeiteffekte auf Insulinempfindlichkeit und β-Zell-Funktion unter vier glukosesenkenden Medikamenten unterstreichen die Bedeutung des Verlusts der β-Zell-Funktion für das Fortschreiten des Typ-2-Diabetes.
Kernaussagen
- HOMA2-%S stieg nur mit Glargin im ersten Jahr
- β-Zell-Antworten nahmen nach anfänglichem Anstieg ab
- Nach 5 Jahren waren CPI und C-Peptid-Antwort unter Liraglutid am höchsten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 11.01.2024. Verfasst von Neda Rasouli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, and VA Eastern Colorado Health…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Metformin, Sulfonylurea Compounds. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To compare the long-term effects of glucose-lowering medications (insulin glargine U-100, glimepiride, liraglutide, and sitagliptin) when added to metformin on insulin sensitivity and β-cell function. RESEARCH DESIGN AND METHODS In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) cohort with type 2 diabetes (n = 4,801), HOMA2 was used to estimate insulin sensitivity (HOMA2-%S) and fasting β-cell function (HOMA2-%B) at baseline and 1, 3, and 5 years on treatment. Oral glucose tolerance test β-cell responses (C-peptide index [CPI] and total C-peptide response [incremental C-peptide/incremental glucose over 120 min]) were evaluated at the same time points. These responses adjusted for HOMA2-%S in regression analysis provided estimates of β-cell function. RESULTS HOMA2-%S increased from baseline to year 1 with glargine and remained stable thereafter, while it did not change from baseline in the other treatment groups. HOMA2-%B and C-peptide responses were increased to variable degrees at year 1 in all groups but then declined progressively over time. At year 5, CPI was similar between liraglutide and sitagliptin, and higher for both than for glargine and glimepiride [0.80, 0.87, 0.74, and 0.64 (nmol/L)/(mg/dL) * 100, respectively; P < 0.001], while the total C-peptide response was greatest with liraglutide, followed in descending order by sitagliptin, glargine, and glimepiride [1.54, 1.25, 1.02, and 0.87 (nmol/L)/(mg/dL) * 100, respectively, P < 0.001]. After adjustment for HOMA2-%S to obtain an estimate of β-cell function, the nature of the change in β-cell responses reflected those in β-cell function. CONCLUSIONS The differential long-term effects on insulin sensitivity and β-cell function of four different glucose-lowering medications when added to metformin highlight the importance of the loss of β-cell function in the progression of type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, and VA Eastern Colorado Health Care System, Aurora, CO.
- The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
- Icahn School of Medicine, Mount Sinai Morningside, New York, NY.
- Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati College of Medicine and Cincinnati VA Medical Center, Cincinnati, OH.
- University of Texas Health Science Center, San Antonio, TX.
- VA San Diego Healthcare System, San Diego, CA.
ORCID-Profile: Neda Rasouli, Ralph A DeFronzo, José A Luchsinger, William I Sivitz, William V Tamborlane, Kristina M Utzschneider, Steven E Kahn
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- CDC HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Centers for Disease Control and Prevention
- The American Diabetes Association
- The National Heart, Lung, and Blood Institute
Zitieren
APA
Rasouli, N., Younes, N., Ghosh, A., Albu, J., Cohen, R. M., DeFronzo, R. A., Diaz, E., Sayyed Kassem, L., Luchsinger, J. A., McGill, J. B., Sivitz, W. I., Tamborlane, W. V., Utzschneider, K. M., Kahn, S. E., & GRADE Research Group (2024). Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care, 47(4), 580-588. https://doi.org/10.2337/dc23-1070
Vancouver
Rasouli N, Younes N, Ghosh A, Albu J, Cohen RM, DeFronzo RA, et al. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care. 2024;47(4):580-588. doi:10.2337/dc23-1070
BibTeX
@article{Rasouli2024,
author = {Rasouli, Neda and Younes, Naji and Ghosh, Alokananda and Albu, Jeanine and Cohen, Robert M and DeFronzo, Ralph A and Diaz, Elsa and Sayyed Kassem, Laure and Luchsinger, José A and McGill, Janet B and Sivitz, William I and Tamborlane, William V and Utzschneider, Kristina M and Kahn, Steven E and GRADE Research Group, GRADE Research Group},
title = {Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {4},
pages = {580--588},
doi = {10.2337/dc23-1070}
}
EUVIMED